Janssen mulls further risk-sharing agreements for new Velcade indication
This article was originally published in Scrip
Executive Summary
Janssen is considering more risk-sharing agreements as part of its market access strategy for cancer drug Velcade (bortezomib) in its newly approved mantle cell lymphoma (MCL) indication.